For more than two decades, the black box warning on hormone replacement therapy (HRT) cast a long shadow over one of the most important treatment conversations in women's health. In November 2025, the U.S. Department of Health and Human Services announced a historic move to initiate removal of that warning from estrogen-containing products used to treat menopausal symptoms. This followed a comprehensive regulatory process that included a formal FDA expert panel convened in July 2025, an extensive review of the accumulated scientific literature, and a public comment period — a multi-layered process designed to weigh the full landscape of current evidence before making any labeling determination. The FDA's planned label revisions will remove references to risks of cardiovascular disease, breast cancer, and probable dementia from HRT products, while retaining the boxed warning for endometrial cancer on systemic estrogen-alone products in women with an intact uterus. As an integrative clinician, I believe this regulatory shift reflects what thoughtful practitioners have understood for years: that the original warning was never a perfect representation of the science, and that millions of women have been undertreated as a result.

The original black box warning was added in 2003, following the publication of data from the Women's Health Initiative (WHI) — at the time, the largest randomized controlled trial of its kind, enrolling over 68,000 postmenopausal women aged 50 to 79. The WHI data linked combined estrogen-progestin therapy to elevated risks of breast cancer, stroke, cardiovascular events, and probable dementia. What followed was a sweeping regulatory and clinical overcorrection: the warning was applied uniformly across all estrogen-containing products regardless of formulation, route of delivery, or dose — including low-dose vaginal estrogen preparations that have minimal systemic absorption. For nearly two decades, that class-based labeling approach deterred countless women and clinicians from pursuing therapies that, for many patients, would have been both safe and effective. A critical flaw in how the original WHI data were interpreted was the failure to account for the age and menopausal timing of study participants. The mean age of WHI enrollees was 63 — well past the typical window of menopause onset — and subsequent reanalysis revealed that the greatest adverse risks were concentrated in women who initiated therapy more than ten years after menopause. This is what researchers now refer to as the "timing hypothesis," and it fundamentally changes how we counsel patients at the point of care. Also, notice the word progestin, this is a synthetic form of progesterone, which has always been demonstrated to be a risk for breast cancer. Integrative doctors such as myself never used it, and now it is rarely used since doctors are aware of the bioidentical form.

A landmark 2024 review published in JAMA by Manson and colleagues, drawing on up to 20 years of WHI follow-up data, found that women below age 60 experienced lower rates of adverse events and a more favorable benefit-to-risk profile compared to older initiators. The WHI data, properly contextualized, support the use of hormone therapy in early menopause for the treatment of moderate-to-severe vasomotor symptoms — the FDA-approved indication it was always best suited for. Leading professional organizations have aligned with this evidence. The North American Menopause Society (NAMS) has affirmed that hormone therapy remains the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and genitourinary syndrome of menopause, and that women younger than 60, or within ten years of their final menstrual period, generally have a favorable benefit-risk ratio

From an integrative medicine perspective, what I find most valuable about this regulatory evolution is the emphasis on individualization. The FDA's updated approach will move away from class-based labeling — which applied identical language to all estrogen products regardless of evidence — and toward tailored safety information that reflects the actual risk profile of each specific product. This is how integrative care has always approached complex clinical decisions: not through blanket protocols, but through individualized risk assessment, shared decision-making, and ongoing monitoring. For patients who are candidates for systemic therapy — those under 60, within a decade of menopause onset, and without significant contraindications such as a history of breast cancer, blood clots, active liver disease, or unexplained bleeding — HRT can meaningfully improve quality of life. Side effects do exist and deserve transparent discussion: systemic therapy may cause breast tenderness, bloating, or changes in bleeding patterns, and carries less common risks including venous thromboembolism and gallbladder disease. But in a healthy, appropriately selected patient, the absolute magnitude of these risks is small, and they must be weighed against the substantial burden of undertreated menopausal symptoms on sleep, cognition, sexual function, bone density, and emotional well-being.

One area where the evidence is expanding and deserves particular attention in clinical practice is the question of age limits for ongoing HRT. It has long been conventional recommendations that hormone therapy should be discontinued at age 65. Emerging data challenges this assumption. A 2024 retrospective analysis presented at The Menopause Society's Annual Meeting examined more than 100 women aged 65 and older who were continuing HRT, with a mean age of 71 years and nearly 8% aged 80 or older. These women had been on hormone therapy for an average of 18 years, and over 40% for more than two decades. The most common reasons for continuing were persistent hot flashes, quality of life, and reduction in chronic pain — and notably, no strokes, myocardial infarctions, or uterine cancers were observed in the cohort. Most were using transdermal estrogen, consistent with the safer cardiovascular profile of non-oral delivery routes. The Menopause Society's own 2022 Hormone Therapy Position Statement acknowledges that women over 65 can appropriately continue HRT with individualized counseling and regular risk reassessment — and this emerging evidence supports that guidance. For women of any age, the question should never be "how old is too old for hormones?" but rather "what are this patient's current symptoms, risks, and goals, and what does the evidence say for someone in her specific clinical situation?" That is the integrative standard of care, and it is the standard the science is now catching up to affirm.

References

American College of Obstetricians and Gynecologists. (2025, November 10). ACOG president says label change on estrogen will increase access to hormone therapy. https://www.acog.org/news/news-releases/2025/11/acog-president-says-label-change-on-estrogen-will-increase-access-to-hormone-therapy

American College of Obstetricians and Gynecologists. (2014, reaffirmed 2024). ACOG practice bulletin no. 141: Management of menopausal symptoms. Obstetrics & Gynecology, 123(1), 202–216. https://doi.org/10.1097/01.AOG.0000441353.20693.78

Chang, J. G., Lewis, M. N., & Wertz, M. C. (2023, July 15). Managing menopausal symptoms: Common questions and answers. American Family Physician. https://www.aafp.org/pubs/afp/issues/2023/0700/menopausal-symptoms.html

Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023). Management of menopausal symptoms: A review. JAMA, 329(5), 405–420. https://doi.org/10.1001/jama.2022.24140

Goel, M., & Wolfman, W. (2024, September 10–14). Retrospective analysis of the use of menopausal hormone therapy in women more than 65 years of age: First Canadian experience [Conference presentation]. The Menopause Society 2024 Annual Meeting, Chicago, IL, United States.

Manohar, R., Ugwuneri, J., Oppong, C., Etsey, M., & Lazar, T. (2025, December 5). Rethinking hormone therapy: From black box warnings to individualized care for menopause. American Medical Women's Association. https://amwa-doc.org/rethinking-hormone-therapy-from-black-box-warnings-to-individualized-care-for-menopause/

Manson, J. E., Crandall, C. J., Rossouw, J. E., Chlebowski, R. T., Anderson, G. L., Stefanick, M. L., Aragaki, A. K., Cauley, J. A., Wells, G. L., LaCroix, A. Z., Thomson, C. A., Neuhouser, M. L., Van Horn, L., Kooperberg, C., Howard, B. V., Tinker, L. F., Wactawski-Wende, J., Shumaker, S. A., & Prentice, R. L. (2024). The Women's Health Initiative randomized trials and clinical practice: A review. JAMA, 331(20), 1748–1760. https://doi.org/10.1001/jama.2024.6542

The Menopause Society. (2024, September 4). Ongoing individualized hormone therapy appears to have no age limit [Press release]. https://menopause.org/press-releases/ongoing-individualized-hormone-therapy-appears-to-have-no-age-limit

The Menopause Society. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

U.S. Department of Health and Human Services. (2025, November 10). HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy [Press release]. https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html

U.S. Food and Drug Administration. (2025, July 17). FDA expert panel on menopause and hormone replacement therapy. https://www.fda.gov/patients/fda-expert-panels/fda-expert-panel-menopause-and-hormone-replacement-therapy-women-07172025

‍